RC-1416

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameRC-1416
Drug Alias Name重组抗人IL-4Rα和IL-5单域抗体注射液 (RC1416注射液)RC14/16RC-1416
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-5 inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alphaInterleukin-5
Therapy Area/IndicationsDermatitis, AtopicPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing RegeneCore Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing RegeneCore Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A